DR. ROBERT ANDREW DICHMANN, MD

Plain English
This research examined how effective different treatments are for early-stage HER2-positive breast cancer. In a study with 128 participants, those who received trastuzumab alone or in combination with lapatinib showed higher rates of complete cancer response (47% and 52%, respectively) compared to those who received lapatinib alone (25%). This matters because understanding the effectiveness of these therapies can help doctors make better treatment decisions, improving outcomes for patients. Who this helps: Patients with HER2-positive breast cancer.

Plain English
This study looked at how well a drug called carfilzomib works for patients with multiple myeloma who did not respond to their previous treatment with bortezomib. Out of 37 patients who were treated, 43% showed positive results, with an average time without disease progression lasting about 8.3 months, and those who responded remained in remission for an average of 15.8 months. This research is important because it shows that carfilzomib could be a good alternative for patients who are not doing well on bortezomib. Who this helps: This helps patients with multiple myeloma who are not responding to their current treatment.

Plain English
This study examined how physical function and quality of life are affected in frail and elderly patients with advanced colorectal cancer who were treated with the medications capecitabine and bevacizumab. Researchers found that 62% of the 45 patients had a performance status that indicated more limitations in daily activities, and those individuals reported lower quality of life. Overall, quality of life improved after starting treatment, and a better performance in a physical test called the "Get up and Go" was linked to longer survival. Who this helps: This research benefits frail and elderly cancer patients by identifying key factors that may improve their treatment experience and outcomes.

Plain English
This study looked at how well the medications capecitabine and bevacizumab work together for older and frail patients with advanced colon cancer. Out of 45 treated patients, those who completed the treatment had a median progression-free survival of about 6.87 months and a median overall survival of 12.7 months. Although some patients experienced side effects like diarrhea and fatigue, these were manageable, which means this treatment could be a good option for this specific group of patients. Who this helps: This benefits elderly patients and those with poor health who are struggling with metastatic colorectal cancer.

Plain English
Researchers studied a specific gene from E. coli that is important for producing a herbicide called phosphinothricin, which is found in products like Basta. They found that by manipulating this gene, they could significantly increase the amount of the enzyme needed for herbicide production, boosting its levels by up to 80 times in modified bacteria. This finding matters because it provides an easier way to produce a key ingredient for herbicides, potentially making herbicide production more efficient. Who this helps: This helps farmers and agricultural companies producing herbicides.

Plain English
This study examined how guided patient education affects the understanding and management of diabetes in 409 patients, many of whom were initially not well-informed about their condition. After receiving group instruction, there was a noticeable improvement in their knowledge within about 9 months, with 50.3% of patients showing better control of their metabolism, while only 7.9% saw a decline. This improvement is important because better metabolic control can lead to fewer complications from diabetes. Who this helps: This benefits diabetes patients and healthcare providers.

Plain English
This study looked at a new way to classify a pregnancy complication called EPH gestosis and how it relates to the risk of babies dying shortly before or after birth. Researchers reviewed 934 cases and found that 40 babies died, showing a clear link between the mother's gestosis and these deaths. They concluded that using the gestosis index is crucial for predicting the risk of these outcomes and managing the mother's condition throughout her pregnancy. Who this helps: This helps doctors manage the health of pregnant women with EPH gestosis and improve outcomes for their babies.